Rikstotoklinikken Bjerke AS, Postboks 194, Økern, N-0150 Oslo, Norway.
Acta Vet Scand. 2014 Mar 13;56(1):13. doi: 10.1186/1751-0147-56-13.
Gastric ulceration is highly prevalent in horses, and there is a large commercial market for feed-additives and non-licenced products that claim effect for prevention and treatment of gastric ulceration. ImproWin® has been used as a feed additive in horses with anecdotal evidence that it may have some positive effects on gastric ulceration.The aim of this study was to investigate the effect of ImproWin® treatment on spontaneously occurring gastric ulcers of the squamous mucosa in Standardbred and Coldblooded trotting racehorses. The study was performed as a randomised, double-blinded, single centre study with stratified semi cross-over design with breed as stratification factors. The horses were clinically and endoscopically examined prior to start and after three weeks of treatment. The ulcerations were scored in accordance with Equine Gastric Ulcer Council (EGUC) recommendations on a 5 point scale and on a 10 cm Visual Analogue Scale (VAS). The patients were responder-classified after 3 weeks. Responders in need of ulcer treatment were randomly allocated to 2 or 4 weeks of additional treatment. Non-responders to placebo were crossed to ImproWin®.
The 5-point EGUC score and VAS recorded score was significantly reduced (P ≤ 0.01) in both groups after 3 weeks of treatment. From 3 weeks to the end of treatment the score was further significantly reduced in the ImproWin® group (P ≤ 0.05). At the end of treatment, 78% in the ImproWin® group and 54.8% in the placebo group were classified as responders. The difference was significant (P = 0.04).
ImproWin® may aid the healing process of ulcers of the gastric squamous mucosa of trotters.
胃溃疡在马中非常普遍,市场上有大量的饲料添加剂和未经许可的产品声称可预防和治疗胃溃疡,这些产品很受欢迎。ImproWin®已作为一种饲料添加剂用于马,有传闻称它可能对胃溃疡有一些积极的影响。本研究旨在调查 ImproWin®治疗对盛装马和冷血走马的鳞状黏膜自发性溃疡的影响。该研究采用随机、双盲、单中心研究设计,采用分层半交叉设计,以品种为分层因素。在开始治疗前和治疗 3 周后,对马匹进行临床和内镜检查。溃疡按照马胃溃疡委员会(EGUC)的建议进行 5 分制评分和 10cm 视觉模拟评分(VAS)。治疗 3 周后对患者进行应答分类。需要溃疡治疗的应答者随机分配接受 2 或 4 周的额外治疗。安慰剂无应答者交叉到 ImproWin®组。
治疗 3 周后,两组的 5 分 EGUC 评分和 VAS 记录评分均显著降低(P≤0.01)。从 3 周到治疗结束,ImproWin®组的评分进一步显著降低(P≤0.05)。治疗结束时,ImproWin®组 78%的患者和安慰剂组 54.8%的患者被归类为应答者。差异具有统计学意义(P=0.04)。
ImproWin®可能有助于促进盛装马和冷血走马的胃鳞状黏膜溃疡的愈合过程。